Analysis of Dynamic Efficacy Endpoints of the Nix-TB Trial

BACKGROUND: Safer, better, and shorter treatments for multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) are an urgent global health need. The phase 3 clinical trial Nix-TB (NCT02333799) tested a 6-month treatment of MDR and XDR-TB consisting of high-dose linezolid, bed...

Descripción completa

Detalles Bibliográficos
Autores principales: Solans, Belén P, Imperial, Marjorie Z, Olugbosi, Morounfolu, Savic, Rada M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249992/
https://www.ncbi.nlm.nih.gov/pubmed/36804834
http://dx.doi.org/10.1093/cid/ciad051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249992/
https://www.ncbi.nlm.nih.gov/pubmed/36804834
http://dx.doi.org/10.1093/cid/ciad051

Ejemplares similares